A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus; Asthma
• Intervention / Treatment: Drug: Subcutaneous Insulin; Drug: Inhaled Insulin

• Study Type: Interventional
• Enrollment (Actual): 288
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • RS
    • Porto Alegre, RS, Brazil, 90035-170
      • Pfizer Investigational Site
  • SP
    • Campinas, SP, Brazil, 13083-900
      • Pfizer Investigational Site
    • Sao Paulo, SP, Brazil, 01244-030
      • Pfizer Investigational Site
  • Sao Paulo
    • SP, Sao Paulo, Brazil, 04231-030
      • Pfizer Investigational Site
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T5J 3N4
      • Pfizer Investigational Site
    • Red Deer, Alberta, Canada, T4N 6V7
      • Pfizer Investigational Site
  • British Columbia
    • Victoria, British Columbia, Canada, V8R 1J8
      • Pfizer Investigational Site
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A 1R9
      • Pfizer Investigational Site
    • Winnipeg, Manitoba, Canada, R3E 3P4
      • Pfizer Investigational Site
  • Ontario
    • Burlington, Ontario, Canada, L7M 4Y1
      • Pfizer Investigational Site
    • London, Ontario, Canada, N6A 4V2
      • Pfizer Investigational Site
  • Quebec
    • Laval, Quebec, Canada, H7T 2P5
      • Pfizer Investigational Site
    • Montreal, Quebec, Canada, H1T 2M4
      • Pfizer Investigational Site
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Pfizer Investigational Site
• Costa Rica
  • San Jose, Costa Rica
    • Pfizer Investigational Site
• Germany
  • Neuss, Germany, 41460
    • Pfizer Investigational Site
• United States
  • Arizona
    • Glendale, Arizona, United States, 85306
      • Pfizer Investigational Site
    • Peoria, Arizona, United States, 85381
      • Pfizer Investigational Site
    • Phoenix, Arizona, United States, 85004
      • Pfizer Investigational Site
    • Phoenix, Arizona, United States, 85006
      • Pfizer Investigational Site
    • Phoenix, Arizona, United States, 85016
      • Pfizer Investigational Site
    • Tucson, Arizona, United States, 85715
      • Pfizer Investigational Site
  • Arkansas
    • Jonesboro, Arkansas, United States, 72401
      • Pfizer Investigational Site
    • Searcy, Arkansas, United States, 72143
      • Pfizer Investigational Site
  • California
    • Berkeley, California, United States, 94705
      • Pfizer Investigational Site
    • Beverly Hills, California, United States, 90211
      • Pfizer Investigational Site
    • Fresno, California, United States, 93720
      • Pfizer Investigational Site
    • Greenbrae, California, United States, 94904
      • Pfizer Investigational Site
    • Huntington Beach, California, United States, 92648
      • Pfizer Investigational Site
    • Los Angeles, California, United States, 90073
      • Pfizer Investigational Site
    • Riverside, California, United States, 92506
      • Pfizer Investigational Site
    • San Diego, California, United States, 92116
      • Pfizer Investigational Site
    • San Diego, California, United States, 92114
      • Pfizer Investigational Site
    • Tustin, California, United States, 92780
      • Pfizer Investigational Site
  • Colorado
    • Boulder, Colorado, United States, 80304
      • Pfizer Investigational Site
    • Denver, Colorado, United States, 80220
      • Pfizer Investigational Site
    • Denver, Colorado, United States, 80209
      • Pfizer Investigational Site
    • Denver, Colorado, United States, 80206
      • Pfizer Investigational Site
  • Connecticut
    • Waterbury, Connecticut, United States, 06708
      • Pfizer Investigational Site
  • Delaware
    • Newark, Delaware, United States, 19713
      • Pfizer Investigational Site
  • Florida
    • Chiefland, Florida, United States, 32626
      • Pfizer Investigational Site
    • Clearwater, Florida, United States, 33756
      • Pfizer Investigational Site
    • Clearwater, Florida, United States, 33765
      • Pfizer Investigational Site
    • Melbourne, Florida, United States, 32901
      • Pfizer Investigational Site
    • Miami, Florida, United States, 33144
      • Pfizer Investigational Site
    • West Palm Beach, Florida, United States, 33401
      • Pfizer Investigational Site
    • West Palm Beach, Florida, United States, 33404
      • Pfizer Investigational Site
  • Georgia
    • Augusta, Georgia, United States, 30909
      • Pfizer Investigational Site
  • Hawaii
    • Honolulu, Hawaii, United States, 96813
      • Pfizer Investigational Site
    • Honululu, Hawaii, United States, 96814
      • Pfizer Investigational Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Pfizer Investigational Site
    • Normal, Illinois, United States, 61761
      • Pfizer Investigational Site
  • Indiana
    • Evansville, Indiana, United States, 47713
      • Pfizer Investigational Site
    • Indianapolis, Indiana, United States, 46250
      • Pfizer Investigational Site
  • Iowa
    • Des Moines, Iowa, United States, 50314
      • Pfizer Investigational Site
    • Dubuque, Iowa, United States, 52001
      • Pfizer Investigational Site
    • Dubuque, Iowa, United States, 52002
      • Pfizer Investigational Site
  • Kansas
    • Wichita, Kansas, United States, 67203
      • Pfizer Investigational Site
  • Louisiana
    • Bossier City, Louisiana, United States, 71111
      • Pfizer Investigational Site
  • Massachusetts
    • North Dartmouth, Massachusetts, United States, 02747
      • Pfizer Investigational Site
    • Springfield, Massachusetts, United States, 01103
      • Pfizer Investigational Site
    • Springfield, Massachusetts, United States, 01107
      • Pfizer Investigational Site
    • Waltham, Massachusetts, United States, 02453
      • Pfizer Investigational Site
  • Minnesota
    • Brooklyn Center, Minnesota, United States, 55430
      • Pfizer Investigational Site
  • Missouri
    • St. Louis, Missouri, United States, 63141
      • Pfizer Investigational Site
  • Montana
    • Butte, Montana, United States, 59701
      • Pfizer Investigational Site
  • Nevada
    • Henderson, Nevada, United States, 89015
      • Pfizer Investigational Site
    • Las Vegas, Nevada, United States, 89103
      • Pfizer Investigational Site
    • Las Vegas, Nevada, United States, 89128
      • Pfizer Investigational Site
    • North Las Vegas, Nevada, United States, 89032
      • Pfizer Investigational Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131-5666
      • Pfizer Investigational Site
  • New York
    • Buffalo, New York, United States, 14209
      • Pfizer Investigational Site
    • New York, New York, United States, 10029
      • Pfizer Investigational Site
  • Ohio
    • Cincinnati, Ohio, United States, 45231
      • Pfizer Investigational Site
    • Cincinnati, Ohio, United States, 45242
      • Pfizer Investigational Site
    • Cincinnati, Ohio, United States, 45219
      • Pfizer Investigational Site
    • Dayton, Ohio, United States, 45402
      • Pfizer Investigational Site
    • Toledo, Ohio, United States, 43608
      • Pfizer Investigational Site
    • Toledo, Ohio, United States, 43606
      • Pfizer Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73103
      • Pfizer Investigational Site
  • Oregon
    • Medford, Oregon, United States, 97504
      • Pfizer Investigational Site
    • Portland, Oregon, United States, 97219
      • Pfizer Investigational Site
    • Portland, Oregon, United States, 97210
      • Pfizer Investigational Site
  • Pennsylvania
    • Lansdale, Pennsylvania, United States, 19446
      • Pfizer Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15243
      • Pfizer Investigational Site
  • South Carolina
    • Spartanburg, South Carolina, United States, 29303
      • Pfizer Investigational Site
    • Spartanburg, South Carolina, United States, 29307
      • Pfizer Investigational Site
  • Tennessee
    • Bartlett, Tennessee, United States, 38133
      • Pfizer Investigational Site
    • Memphis, Tennessee, United States, 38119
      • Pfizer Investigational Site
    • Nashville, Tennessee, United States, 37203
      • Pfizer Investigational Site
  • Texas
    • Beaumont, Texas, United States, 77701
      • Pfizer Investigational Site
    • Dallas, Texas, United States, 75231
      • Pfizer Investigational Site
    • Houstan, Texas, United States, 77079
      • Pfizer Investigational Site
    • Houston, Texas, United States, 77030
      • Pfizer Investigational Site
    • Houston, Texas, United States, 77043
      • Pfizer Investigational Site
    • San Antonio, Texas, United States, 78229
      • Pfizer Investigational Site
    • San Antonio, Texas, United States, 78237
      • Pfizer Investigational Site
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Pfizer Investigational Site
    • Richmond, Virginia, United States, 23229
      • Pfizer Investigational Site
    • Richmond, Virginia, United States, 23235
      • Pfizer Investigational Site
  • Washington
    • Spokane, Washington, United States, 99202
      • Pfizer Investigational Site
    • Spokane, Washington, United States, 99204
      • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 77 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diabetes Mellitus (Type 1 or Type 2) currently controlled with injected insulin
• Mild intermittent or mild to moderate persistent asthma

Exclusion Criteria:

• Poorly controlled, unstable or steroid-dependent asthma, insulin pump therapy, smoking

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Subcutaneous Insulin	Drug: Subcutaneous Insulin; Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Experimental: Inhaled Insulin	Drug: Inhaled Insulin; Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)	Annualized rates of change (slope throughout time from baseline to end of study[visit]) for forced expiratory volume in 1 second (FEV1) (liters per year [L/yr]) measured 30 minutes following the administration of albuterol.	Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)	Annualized rates of change (slope throughout time from baseline to end of study[visit]) for hemoglobin-adjusted carbon monoxide diffusion capacity (DLco)in milliliters per minute/millimeters of mercury/year (ml/min/mmHg/yr) measured 30 minutes following the administration of albuterol.	Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)	Change from Baseline at each visit in post-bronchodilator forced expiratory volume in one second (FEV1). FEV1 was measured in liters (L) 30 minutes following the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus baseline value.	Baseline through Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)	Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of albuterol. Change from Baseline: mean DLco (mL/min/mmHg) at observation minus baseline value.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)	Change from Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at each visit. FEV1 was measured in liters (L) before the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus mean baseline value.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)	Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation carried Forward (LOCF)
Change From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)	Change from Baseline in Pre-Insulin Forced Expiratory Volume in one second (FEV1) measured in liters (L): change = FEV1 at observation minus FEV1 at Baseline.	Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward
Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)	Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.	Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)	Change from baseline in Post-bronchodilator Forced Vital Capacity (FVC) measured in liters (L) 30 minutes following the administration of albuterol: change = FVC at observation minus FVC at Baseline.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol	Responsiveness was the percent change from the forced expiratory volume in 1 second (FEV1) value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as [(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1] multiplied by 100.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52
Percent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)	Percent predicted change from Baseline in post-bronchodilator forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in post-bronchdilator FEV1 measured in liters (L): (observed value minus Baseline value) divided by Baseline value *100%.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin	Change from Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in one second (FEV1) measured 10 and 60 minutes after the first daily dose of insulin. Insulin dose responsiveness = the difference between FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post dose FEV1 value minus predose FEV1 value.	Baseline, Week 9, Week 51
Percent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)	Percent predicted change from Baseline in 10 Minute and 60 Minute post-insulin forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in FEV1 measured in liters (L) 10 and 60 Minutes post-insulin. Percent change = (value at observation minus Baseline value) divided by Baseline value *100%.	Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Change From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin	Carbon Monoxide Diffusing Capacity (DLco) dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin was defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value.	Baseline, Week 9, Week 51
Methacholine Challenge	Methacholine Challange: performed on a subset of subjects using the 5-breath dosimeter method. Subjects were challenged with ascending doses of nebulized methacholine; dosing schedule: 0.03, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 milligrams per milliliter (mg/ml) administered in 5-minute intervals. Forced expiratory volume in 1 second (FEV1) was measured 1-3 minutes after each inhalation of methacholine solution. Testing continued until highest FEV1 decreased by ≥20% from the challenge (post-diluent) reference, or until completion all doses.	1 to 2 days following Weeks -3 and -1 visits, and at Week 11, Week 50, and Week 52 (+5)
Mean Weekly Morning and Evening Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in 1 Second (FEV1)	Subjects measured peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) twice daily and entered the results in an electronic diary. Daily data were used to calculate the mean PEFR and FEV1 for each week (observed weekly mean and change from baseline in weekly mean). For each subject, the mean weekly morning (and evening) PEFR and FEV1 was defined as the sum of the daily morning (and evening) PEFR (and FEV1) measurements during the week divided by the number of non-missing PEFR (and FEV1) measurements during the week.	Week -3 through Week 52
Mean Weekly Number of Puffs of Albuterol Used (Rescue Medication)	All subjects used an electronic symptom diary to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol) daily, immediately upon arising, and again in the evening or before bed.	Daily: Baseline to end of study
Number of Subjects With Step-up and Step-down Changes in Classification of Asthma Severity by Medication Usage	All asthma medication changes during the study were classified as step-up or step-down according to treatment guidelines. Step 1: Intermittant Asthma; Step 2: Mild Persistent Asthma; Step 3: Moderate Persistent Asthma; Step 4: Severe Persistent Asthma. The number of subjects in each step classification of asthma severity were provided at each assessment timepoint for each treatment group, with a shift table indicating the number of subjects moving from each step classification at each timepoint.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Step Classification of Asthma Severity by Medication Usage	Step classification of asthma severity by medication usage. Subjects were classified at each visit according to the medication used on the day of the particular time-point; Step 1: intermittent asthma, Step 2: mild persistent asthma, Step 3: moderate persistent asthma, Step 4: severe persistent asthma. The number (%) of subjects in each step classification were provided at each assessment timepoint with a shift table indicating the number (%) of subjects moving from each step classification at each time-point.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Mean Weekly Asthma Symptom Scores	Mean weekly asthma symptom scores: subjects recorded their asthma symptom scores in an electronic symptom diary twice daily throughout the study, immediately upon awakening (5-10 AM) and in the evening or at bedtime (7-12 PM). Questions included extent of albuterol use, symptoms of wheezing, coughing, activity limitations and sleep; scale 0 (none/fine) to 3 (severe/ continuous/bad night).	Baseline through end of study
Incidence of Non-severe Asthma Exacerbations	Non-severe asthma exacerbation = one of the following: any home monitored morning (4:45 am - 10:15 am) forced expiratory volume in 1 second (FEV1) <80% of the morning baseline for 2 or more consecutive days; or home monitored FEV1 <60% of Baseline at any time. Percent of Baseline = 100*(daily FEV1)/Baseline weekly FEV1. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months.	0 to 1 week to > 12 months
Incidence of Severe Asthma Exacerbations	Severe asthma exacerbation was defined as one of the following: subject received oral (systemic) corticosteriods for the treatment of asthma; or subject had an unscheduled visit to a physician, emergency room, or hospital for the treatment of asthma. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months * 100.	0 to 1 Week to > 12 Months
Number of Systemic Corticosteroid Rescues	Number of subjects who used a systemic corticosteroid at any time during the study, and the total number of systemic corticosteroid rescues. New rescue event = >=2 consecutive days between the end of one event and the start of another event.	Baseline through Week 52
Asthma Control as Measured by the Asthma Control Questionnaire©	Asthma Control Questionnaire©: 6 self-administered questions that assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; 7-point ordinal rating scale from 0 (good control) to 6 (poor control). A seventh question was completed by a health professional on forced expiratory volume in 1 second (FEV1) % predicted using a one-week recall period; scale: 0 (>95% predicted) to 6 (<50% predicted). Overall score = mean of questions 1 - 7.	Baseline, Weeks 4, 12, 26, 39, 52
Baseline Dyspnea Index (BDI)	Total score = the sum of the numeric grades from the three dyspnea index questions. Functional Impairment rating scale: Grade 4 (no impairment) to Grade 0 (very severe impairment); Magnitude of Task rating scale: Grade 4 (extraordinary) to Grade 0 (no task); and Magnitude of Effort rating scale: Grade 4 (extraordinary) to grade 0 (no effort).	run-in period
Transition Dyspnea Index (TDI): Change in Total Score	Transition Dyspnea Index total score = sum of the numeric grades from the three dyspnea index questions: Change in Functional Impairment, Change in Magnitude of Task, and Change in Magnitude of Effort. Rating scale: -3 (major deterioration), -2 (moderate deterioration), -1 (minor deterioration, 0 (no change), +1 (minor improvement), +2 (moderate improvement), +3 (major improvement).	Week 4, Week 12, Week 26, Week 39, Week 52
Glycosylated Hemoglobin (HbA1c)	Glycosylated Hemoglobin (HbA1c): observed mean values at Baseline and each observation, and change from Baseline. Change from Baseline = mean HbA1c at observation minus mean HbA1c at Baseline.	Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Fasting Plasma Glucose	Fasting plasma glucose (milligrams per deciliter [mg/dL]) at Baseline, and change from Baseline. Change from baseline: mean of value of fasting plasma glucose in mg/dL at observation minus baseline value.	Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Body Weight: Mean Baseline and Change From Baseline	Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus baseline value.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 11, Week 12, Week 18, Wek 26, Week 39, Week 50, Week 51, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)	Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight: long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg. Subcutaneous Insulin reported in units.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight	Total daily dose of long-acting insulin adjusted for body weight (units per kilogram [kg]). Long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg/kg. Subcutaneous Insulin reported in units/kg.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)	Average Total Daily Insulin Dose: short-acting insulin (milligrams [mg]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight	Total Daily Short-Acting Insulin Dose adjusted for body weight (units divided by kg). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.	Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Lipids: Median Change From Baseline to Last Observation	Lipids: median changes (milligrams per deciliter [mg/dL]) from Baseline median to last observation in cholesterol (random), triglycerides (random), high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol. Normalized data was used in the computations. Last observation = last observation while on study drug or during the lag. Measures of dispersion for median changes in lipids were not determined.	Baseline to Last Observation
Hypoglycemic Event Rates	A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate = total events divided by subject months. Subject months = elapsed number of months a subject was in the study in each time interval.	0 to 1 month to 11 to 12 months, and Overall
Severe Hypoglycemic Event Rates	Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); blood glucose measurement was ≤ 49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Crude event rate = number of events divided by 100 subject-months. Subject months = elapsed number of months subject was in study in each time interval.	0 to 1 month to 11 to 12 months, and Overall

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: January 1, 2003
• Primary Completion (Actual): October 1, 2008
• Study Completion (Actual): October 1, 2008

Study Registration Dates

• First Submitted: August 29, 2005
• First Submitted That Met QC Criteria: August 29, 2005
• First Posted (Estimate): August 31, 2005

Study Record Updates

• Last Update Posted (Estimate): June 2, 2010
• Last Update Submitted That Met QC Criteria: May 26, 2010
• Last Verified: October 1, 2009

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Endocrine System Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Diabetes Mellitus; Asthma; Hypoglycemic Agents; Physiological Effects of Drugs; Insulin; Insulin, Globin Zinc
• Other Study ID Numbers: A2171028